1889. Poor immunogenicity of one-dose 13-valent pneumococcal conjugated vaccine in hematopoietic stem cell transplantation recipients
Session: Poster Abstract Session: Vaccines: PCV
Saturday, October 10, 2015
Room: Poster Hall
  • HSCT PCV13.pdf (468.4 kB)
  • Background: Hematopoietic stem cell transplantation (HSCT) recipients were at significant risk for invasive pneumococcal disease while no study evaluated the immunogenicity of 1-dose 13-valent pneumococcal conjugated vaccine (PCV13) in this setting.

    Methods: HSCT recipients naïve for pneumococcal vaccine received 1-dose PCV13 at least 3 months after HSCT. Anti-capsular antibody responses against 4 serotypes (6B, 14, 19F and 23F) at baseline and 1, 3, 6, 9, and 12 months following vaccination were measured. Significant antibody responses were defined as 2-fold or greater increase of antibody levels compared with the baseline level.

    Results: From May 2014 to Apr 2015, a total of 40 HSCT recipients with a median age of 43.5 (IQR 35-53) were enrolled for 1-dose PCV13 after a median interval of 212.5 (IQR 126-355) days post-HSCT. Acute myeloid leukemia (28%) and lymphoma (28%) were the predominant underlying diseases. Of 32 patients with available antibody responses, significant responses against 6B, 14, 19F and 23F were observed in 9.4%, 31.2%, 12.5%, and 15.6% with geometric mean of 0.77, 4.86, 1.67, and 0.72 microgram/mL, respectively, 1-month post PCV13; 16% (4/25), 28% (7/25), 24% (6/25), and 24% (6/25) with geometric mean of 0.82, 4.74, 1.66, 0.6 microgram/mL, respectively, 3-months post PCV13, and all 42.9% (3/7) with geometric mean of 1.17, 8.07, 2.10, 0.95 microgram/mL, respectively, 6-months post PCV13.

    Conclusion: One-does PCV13 might be insufficient for HSCT recipients, and more doses of PCV13 might be needed.

    Hsin-Yun Sun, MD, Jia-Hau Liu, MD, Bor-Sheng Ko, MD, Chi-Cheng Li, MD, Ming Yao, MD, Jih-Lu Tang, MD and Wang-Huei Sheng, PhD, Internal Medicine, Natl Taiwan Univ Hosp, Taipei, Taiwan


    H. Y. Sun, None

    J. H. Liu, None

    B. S. Ko, None

    C. C. Li, None

    M. Yao, None

    J. L. Tang, None

    W. H. Sheng, None

    See more of: Vaccines: PCV
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.